These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27006706)

  • 1. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.
    Duvnjak L; Blaslov K
    Diabetol Metab Syndr; 2016; 8():26. PubMed ID: 27006706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
    Park SH; Nam JY; Han E; Lee YH; Lee BW; Kim BS; Cha BS; Kim CS; Kang ES
    Medicine (Baltimore); 2016 Aug; 95(32):e4543. PubMed ID: 27512877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital.
    Mak WY; Nagarajah JR; Abdul Halim H; Ramadas A; Mohd Pauzi Z; Pee LT; Jagan N
    J Pharm Policy Pract; 2020; 13():34. PubMed ID: 32566235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.
    Choe EY; Cho Y; Choi Y; Yun Y; Wang HJ; Kwon O; Lee BW; Ahn CW; Cha BS; Lee HC; Kang ES
    Diabetes Metab J; 2014 Jun; 38(3):211-9. PubMed ID: 25003075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.
    Zografou I; Sampanis C; Gkaliagkousi E; Iliadis F; Papageorgiou A; Doukelis P; Vogiatzis K; Douma S
    Hormones (Athens); 2015; 14(1):118-25. PubMed ID: 25402372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
    Nishida Y; Takahashi Y; Tezuka K; Akimoto H; Nakayama T; Asai S
    BMC Pharmacol Toxicol; 2020 Apr; 21(1):28. PubMed ID: 32317005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
    Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
    Elhini SH; Hussien AK; Omran AAE; Elsayed AA; Saeed H
    Clin Exp Pharmacol Physiol; 2021 Dec; 48(12):1589-1602. PubMed ID: 34333803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
    Wang X; Zhao B; Sun H; You H; Qu S
    Front Endocrinol (Lausanne); 2022; 13():866189. PubMed ID: 36072931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.
    Saglietti G; Placentino G; Schellino A
    Clin Drug Investig; 2014 Jul; 34(7):513-9. PubMed ID: 24788571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Rizzo MR; Barbieri M; Marfella R; Paolisso G
    Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
    Kothny W; Lukashevich V; Foley JE; Rendell MS; Schweizer A
    Diabetologia; 2015 Sep; 58(9):2020-6. PubMed ID: 26067186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
    Matsubara J; Sugiyama S; Akiyama E; Iwashita S; Kurokawa H; Ohba K; Maeda H; Fujisue K; Yamamoto E; Kaikita K; Hokimoto S; Jinnouchi H; Ogawa H
    Circ J; 2013; 77(5):1337-44. PubMed ID: 23386232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.